Literature DB >> 17032150

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.

Rutger L van Bezooijen1, J Peter Svensson, Daniël Eefting, Annemieke Visser, Geertje van der Horst, Marcel Karperien, Paul H A Quax, Harry Vrieling, Socrates E Papapoulos, Peter ten Dijke, Clemens W G M Löwik.   

Abstract

UNLABELLED: Sclerostin is an osteocyte-derived negative regulator of bone formation. It inhibits BMP-stimulated bone formation both in vitro and in vivo but has no direct effect on BMP signaling. Instead, sclerostin inhibits Wnt signaling that is required for BMP-stimulated osteoblastic differentiation.
INTRODUCTION: Sclerostin is a member of the Dan family of glycoproteins of which many members have been reported to antagonize BMP activity. Sclerostin has been shown to inhibit BMP-stimulated bone formation, but its mechanism of action seems to be different from classical BMP antagonists. In this study, we investigated the mechanism by which sclerostin inhibits BMP-stimulated bone formation.
MATERIALS AND METHODS: DNA electroporation of calf muscle of mice using expression plasmids for BMP and sclerostin was used to study the effect of sclerostin on BMP-induced bone formation in vivo. Transcriptional profiling using microarrays of osteoblastic cells treated with BMP in the absence or presence of sclerostin was used to find specific growth factor signaling pathways affected by sclerostin. The affected pathways were further studied using growth factor-specific reporter constructs.
RESULTS: BMP-induced ectopic bone formation in calf muscle of mice was prevented by co-expression of sclerostin in vivo. Transcriptional profiling analysis of osteoblastic cultures indicated that sclerostin specifically affects BMP and Wnt signaling out of many other growth signaling pathways. Sclerostin, however, did not inhibit stimulation of direct BMP target genes. Furthermore, we did not obtain any evidence for sclerostin acting as a direct BMP antagonist using a BMP-specific reporter construct. In contrast, sclerostin shared many characteristics with the Wnt antagonist dickkopf-1 in antagonizing BMP-stimulated bone formation and BMP- and Wnt-induced Wnt reporter construct activation.
CONCLUSIONS: Sclerostin inhibits BMP-stimulated bone formation but does not affect BMP signaling. Instead, it antagonizes Wnt signaling in osteoblastic cells. High bone mass in sclerosteosis and van Buchem disease may, therefore, result from increased Wnt signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17032150     DOI: 10.1359/jbmr.061002

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  88 in total

1.  Circulating sclerostin in disorders of parathyroid gland function.

Authors:  Aline G Costa; Serge Cremers; Mishaela R Rubin; Donald J McMahon; James Sliney; Marise Lazaretti-Castro; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

Review 2.  Osteocyte regulation of bone mineral: a little give and take.

Authors:  G J Atkins; D M Findlay
Journal:  Osteoporos Int       Date:  2012-08       Impact factor: 4.507

3.  Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors.

Authors:  Gill Holdsworth; Patrick Slocombe; Carl Doyle; Bernadette Sweeney; Vaclav Veverka; Kelly Le Riche; Richard J Franklin; Joanne Compson; Daniel Brookings; James Turner; Jeffery Kennedy; Rachael Garlish; Jiye Shi; Laura Newnham; David McMillan; Mariusz Muzylak; Mark D Carr; Alistair J Henry; Thomas Ceska; Martyn K Robinson
Journal:  J Biol Chem       Date:  2012-06-13       Impact factor: 5.157

Review 4.  Sclerostin and skeletal health.

Authors:  Maryam Sharifi; Lisa Ereifej; E Michael Lewiecki
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

Review 5.  Osteocytes, mechanosensing and Wnt signaling.

Authors:  Lynda F Bonewald; Mark L Johnson
Journal:  Bone       Date:  2008-01-12       Impact factor: 4.398

6.  Control of the SOST bone enhancer by PTH using MEF2 transcription factors.

Authors:  Olivier Leupin; Ina Kramer; Nicole M Collette; Gabriela G Loots; François Natt; Michaela Kneissel; Hansjoerg Keller
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

7.  Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation.

Authors:  Vaclav Veverka; Alistair J Henry; Patrick M Slocombe; Andrew Ventom; Barbara Mulloy; Frederick W Muskett; Mariusz Muzylak; Kevin Greenslade; Adrian Moore; Li Zhang; Jianhua Gong; Xueming Qian; Chris Paszty; Richard J Taylor; Martyn K Robinson; Mark D Carr
Journal:  J Biol Chem       Date:  2009-02-10       Impact factor: 5.157

8.  Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate.

Authors:  Larry Pederson; Ming Ruan; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 9.  The DAN family: modulators of TGF-β signaling and beyond.

Authors:  Kristof Nolan; Thomas B Thompson
Journal:  Protein Sci       Date:  2014-06-02       Impact factor: 6.725

10.  Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.

Authors:  Kristine M Erlandson; MaryAnn O'Riordan; Corrilynn O Hileman; Eric Rapaport; Danielle Labbato; Thomas B Campbell; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-27       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.